Key result
Cockcroft-Gault yields lower eGFR than MDRD, altering CKD staging in ~20% of NSTE-ACS patients.
Why the study?
Assessment of glomerular filtration rate is important for antithrombotic dose adjustment in NSTE ACS patients, prompting a comparison of the Cockcroft-Gault and MDRD formulae.
Does the Cockcroft-Gault formula differ from the Modification of Diet in Renal Disease formula in estimating glomerular filtration rate and guiding antithrombotic dose adjustments in patients with non-ST-segment elevation acute coronary syndromes?
Observational (n=46,942)
Yes
Does the Cockcroft-Gault formula differ from the Modification of Diet in Renal Disease formula in estimating glomerular filtration rate and guiding antithrombotic dose adjustments in patients with non-ST-segment elevation acute coronary syndromes?
Because CKD classification and required antithrombotic dose adjustments differ in 20% of NSTE ACS patients when comparing MDRD to Cockcroft-Gault, dosing based on the Cockcroft-Gault formula is preferable to minimize bleeding risk, particularly in small, female, or elderly patients.
Answers are grounded in this paper and cite their sources.
May affect antithrombotic dosing decisions in ACS; leaves open preferred GFR formula for renal adjustment.
Objectives Our purpose was to compare formulae for estimating glomerular filtration rate (GFR) in non-ST-segment elevation acute coronary syndromes (NSTE ACS) patients. Background Assessment of GFR is important for antithrombotic dose adjustment in NSTE ACS patients. Methods We assessed estimated glomerular filtration rate (eGFR) with Cockcroft-Gault (C-G) and Modification of Diet in Renal Disease (MDRD) formulae in 46,942 NSTE ACS patients from 408 CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association Guidelines) hospitals. Formula agreement was shown continuously and by chronic kidney disease (CKD) stages. We determined in-hospital outcomes and the association between antithrombotic dose adjustment and bleeding for moderate CKD as determined by each formula. Results The median (interquartile range [IQR]) eGFR was 53.2 ml/min (34.7, 75.1 ml/min) by C-G and 65.8 ml/min (47.6, 83.5 ml/min) by MDRD. The mean eGFR was higher with MDRD (approximately 9.1 ml/min), but this difference was greater in age, weight, and gender subgroups. Chronic kidney disease classification differed in 20% of the population and altered when antithrombotic dose adjustment was required by C-G versus MDRD (eptifibatide: 45.7% vs. 27.3%; enoxaparin: 19.0% vs. 9.6%). Conclusions Important CKD disagreements occur in approximately 20% of acute coronary syndrome patients, affecting dosing adjustments in those already susceptible to bleeding. Dosing based on C-G formula is preferable, particularly in the small, female, or elderly patient.
No takes yet. Share an insight, caveat, or question.
Melloni et al. (2008) conducted an observational in Non-ST-segment elevation acute coronary syndromes (NSTE ACS) (n=46,942). Cockcroft-Gault (C-G) formula for eGFR vs. Modification of Diet in Renal Disease (MDRD) formula for eGFR was evaluated on Estimated glomerular filtration rate (eGFR) and chronic kidney disease (CKD) stage agreement (MD -9.1 ml/min). Cockcroft-Gault yielded lower median eGFR than MDRD and differed in CKD classification in 20% of NSTE ACS patients, altering antithrombotic dosing.
Synapse has enriched 10 related papers. Consider them for comparative context: